Literature DB >> 6308066

Angiotensin-converting enzyme and its clinical significance--a review.

P R Studdy, R Lapworth, R Bird.   

Abstract

There have been considerable advances in understanding the metabolic role of the endothelial lining cells of the blood vessels. Angiotensin-converting enzyme activity is concentrated in these cells, especially those lining the pulmonary circulation. The enzyme exerts control over systemic vascular tone indirectly through the powerful pressor effect of angiotensin II. A number of therapeutic agents are now available which directly inhibit converting enzyme activity and thereby effect a reduction in blood pressure. Macrophages are the source of increased angiotensin-converting enzyme activity commonly found in association with active sarcoidosis. A better understanding of this phenomenon may give fresh insight into this puzzling condition. Pulmonary endothelial metabolism is affected by lung injury and it is likely that in this situation changing activities of serum angiotensin converting enzyme may indicate the extent of damage and the response to therapy. The full clinical significance of serum ACE measurements has yet to be established. However, raised activities have been reported in a number of other conditions and diabetes mellitus and hyperthyroidism are of particular current interest. The numerous methods and reference ranges described in the literature for the measurement of serum ACE activity require further assessment, and there is a clear need for an accepted reference method.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6308066      PMCID: PMC498427          DOI: 10.1136/jcp.36.8.938

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  88 in total

1.  In-vivo and in-vitro conversion of angiotensin I to angiotensin II in dog blood.

Authors:  S Oparil; C A Sanders; E Haber
Journal:  Circ Res       Date:  1970-05       Impact factor: 17.367

2.  Angiotensin converting enzyme: method of assay and partial purification.

Authors:  F E Dorer; L T Skeggs; J R Kahn; K E Lentz; M Levine
Journal:  Anal Biochem       Date:  1970-01       Impact factor: 3.365

3.  Evidence for the renal conversion of angiotensin I in the dog.

Authors:  W G Franklin; M J Peach; J P Gilmore
Journal:  Circ Res       Date:  1970-09       Impact factor: 17.367

4.  Conversion of angiotensin I to angiotensin II by cell-free extracts of dog lung.

Authors:  Y S Bakhle
Journal:  Nature       Date:  1968-11-30       Impact factor: 49.962

5.  Physiological and pathological variations of plasma angiotensin II in man. Correlation with renin activity and sodium balance.

Authors:  D J Gocke; J Gerten; L M Sherwood; J H Laragh
Journal:  Circ Res       Date:  1969-05       Impact factor: 17.367

6.  Pressor response to angiotensin I during cardio-pulmonary bypass.

Authors:  P Stanley; P Biron
Journal:  Experientia       Date:  1969-01-15

7.  Fate of angiotensin I in the circulation.

Authors:  K K Ng; J R Vane
Journal:  Nature       Date:  1968-04-13       Impact factor: 49.962

8.  Excretion of hydroxyproline in patients with sarcoidosis.

Authors:  D Massaro; A E Handler; S Katz; R C Young
Journal:  Am Rev Respir Dis       Date:  1966-06

9.  The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cat.

Authors:  S H Ferreira; J R Vane
Journal:  Br J Pharmacol Chemother       Date:  1967-06

10.  Conversion of angiotensin I to angiotensin II.

Authors:  K K Ng; J R Vane
Journal:  Nature       Date:  1967-11-25       Impact factor: 49.962

View more
  35 in total

Review 1.  Ankylosing spondylitis and sarcoidosis--coincidence or association? Case report and review of the literature.

Authors:  G Stucki; A von Felten; R Speich; B A Michel
Journal:  Clin Rheumatol       Date:  1992-09       Impact factor: 2.980

Review 2.  Necrotizing infundibuloneurohypophysitis: case report and literature review.

Authors:  Anick Nater; Luis V Syro; Fabio Rotondo; Bernd W Scheithauer; Veronica Abad; Carolina Jaramillo; Kalman Kovacs; Eva Horvath; Michael Cusimano
Journal:  Endocr Pathol       Date:  2012-09       Impact factor: 3.943

3.  [Manifestations of autoimmune disorders in otorhinolaryngology : Classical symptoms and diagnostic approach].

Authors:  B Hofauer; A Chaker; K Thürmel; A Knopf
Journal:  HNO       Date:  2017-08       Impact factor: 1.284

4.  Chasing the ACE of hearts.

Authors:  Andrew D'Silva; Imad Jassim; John Greenwood; Konrad Grosser
Journal:  BMJ Case Rep       Date:  2013-06-25

5.  Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer.

Authors:  Yoriko Yamazato; Anderson J Ferreira; Kwon-Ho Hong; Srinivas Sriramula; Joseph Francis; Masanobu Yamazato; Lihui Yuan; Chastity N Bradford; Vinayak Shenoy; Suk P Oh; Michael J Katovich; Mohan K Raizada
Journal:  Hypertension       Date:  2009-06-29       Impact factor: 10.190

Review 6.  Membrane protein secretases.

Authors:  N M Hooper; E H Karran; A J Turner
Journal:  Biochem J       Date:  1997-01-15       Impact factor: 3.857

Review 7.  Can pulmonary vasodilators improve survival in cor pulmonale due to hypoxic chronic bronchitis and emphysema?

Authors:  K F Whyte; D C Flenley
Journal:  Thorax       Date:  1988-01       Impact factor: 9.139

8.  A forgotten cause of kidney injury in chronic myelomonocytic leukemia.

Authors:  Tejas V Patel; Helmut G Rennke; J Mark Sloan; Daniel J DeAngelo; David M Charytan
Journal:  Am J Kidney Dis       Date:  2009-01-29       Impact factor: 8.860

9.  Casein fermentate of Lactobacillus animalis DPC6134 contains a range of novel propeptide angiotensin-converting enzyme inhibitors.

Authors:  M Hayes; C Stanton; H Slattery; O O'Sullivan; C Hill; G F Fitzgerald; R P Ross
Journal:  Appl Environ Microbiol       Date:  2007-05-04       Impact factor: 4.792

10.  Effect of enalapril on allergen-induced cutaneous hypersensitivity reaction.

Authors:  J R Snyman; D K Sommers
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.